Mental Health in Visible Skin Disorders: Assessing Anxiety and Depression in vitiligo and alopecia areata patients compared to Healthy Peers

Suad Altubouli; Hana Hafalish; Marfoua Ali

doi:10.69667/lmj.2517314

Authors

Suad Altubouli Department of Dermatology, College of Medicine, Omar Al-Mukhtar University, AL Bayda, Libya https://orcid.org/0009-0008-4780-8855
Hana Hafalish Department of Dermatology, College of Medicine, Omar Al-Mukhtar University, AL Bayda, Libya https://orcid.org/0009-0002-4140-6448
Marfoua Ali Department of Zoology, College of Science, Omar Al-Mukhtar University, AL Bayda, Libya https://orcid.org/0000-0003-0814-8651

DOI:

https://doi.org/10.69667/lmj.2517314

Keywords:

Vitiligo, Alopecia Areata, Anxiety & Depression.

Abstract

Alopecia areata is characterized by non-scarring scalp complete terminal hair loss, and vitiligo is characterized by skin pigment loss. Alopecia and vitiligo are distinct, heterogeneous, and complex diseases, in most cases resistance to treatment. The current study aimed to evaluate and compare the Anxiety and Depression levels within patients who were diagnosed with Vitiligo and Alopecia-areata against the control group of healthy individuals. A total of 150 participants were recruited: 50 with vitiligo, 50 with alopecia areata, and 50 healthy controls. Patients who visited the outpatient dermatology clinic at Medical Centre at Al-Beyda City from January to December 2023 have been included in this Study. The Hospital Anxiety and Depression Scale (HADS) was used to evaluate ''Depression and Anxiety''. The findings showed that elevated anxiety and despair scores in both patient groups relative to the healthy control group (p < 0.001). However, current results showed that no significant difference was observed between the vitiligo and alopecia areata groups (p > 0.05). These findings highlight the psychological burden associated with chronic dermatological conditions and emphasize the need for integrated mental health support in dermatological care

References

Rork JF, Rashighi M, Harris JE. Understanding autoimmunity of vitiligo and alopecia areata. Curr Opin Pediatr. 2016;28(4):463–9.

Musbah F. Clinical correlation between alopecia areata and salmon patches: a case series. AlQalam J Med Appl Sci. 2024 May 5:322–6.

Bergqvist C, Ezzedine K. Vitiligo: a review. Dermatology. 2020;236(6):571–92.

Hunt N, McHale S. The psychological impact of alopecia. BMJ. 2005;331(7522):951–3.

Sampogna F, Raskovic D, Guerra L, Pedicelli C, Taboli S, Leoni L, et al. Identification of categories at risk for high quality of life impairment in patients with vitiligo. Br J Dermatol. 2018;179(2):351–8.

Dalgard FJ, Gieler U, Tomas-Aragones L, Lien L, Poot F, Jemec GB, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135(4):984–91.

Cruz S, Lei DK, Carr H, Rosenblatt A. The psychosocial impacts of vitiligo, psoriasis, and alopecia areata on pediatric patients. Dermatol Online J. 2023;29(2):1–11.

Talaei A, Nahidi Y, Kardan G, Jarahi L, Aminzadeh B, Jahed Taherani H, et al. Temperament-character profile and psychopathologies in patients with alopecia areata. J Gen Physiol. 2017;144(3):206–17.

Sharma VK, Bhatia R. Vitiligo and the psyche. Br J Dermatol. 2017;177(3):612–3.

Bibeau K, Ezzedine K, Harris JE, van Geel N, Grimes P, Parsad D, et al. Mental health and psychosocial quality-of-life burden among patients with vitiligo: findings from the global VALIANT study. JAMA Dermatol. 2023;159(10):1124–8.

Okhovat JP, Marks DH, Manatis-Lornell A, Hagigeorges D, Locascio JJ, Senna MM. Association between alopecia areata, anxiety, and depression: a systematic review and meta-analysis. J Am Acad Dermatol. 2023;88(5):1040–50.

Yildiz H, Zincir S. Anxiety and depression in patients with alopecia areata in Eskisehir, Turkey. Clin Cosmet Investig Dermatol. 2023;16:2443–50.

Ghalamkarpour F, Araghi F, Tabari M, Moslemi Haghighi S, Pourgholi E. Comparing quality of life, anxiety, depression, sleep disturbance, and associated factors in vitiligo and alopecia areata patients. J Cosmet Dermatol. 2024;23(5):1808–15.

Atış G, Tekin A, Ferhatoğlu ZA, Göktay F, Yaşar Ş, Aytekin S. Type D personality and quality of life in alopecia areata and vitiligo patients: a cross-sectional study in a Turkish population. Turk J Dermatol. 2021;55:87–91.

Jagtiani A, Nishal P, Jangid P, Sethi S, Dayal S, Kapoor A. Depression and suicidal ideation in patients with acne, psoriasis, and alopecia areata. J Ment Health Hum Behav. 2017;22:50.

Papadopoulos L, Bor R, Legg C. Coping with the disfiguring effects of vitiligo: a preliminary investigation into the effects of cognitive-behavioural therapy. Br J Med Psychol. 1998;71(3):385–96.

Ruiz-Doblado S, Carrizosa A, García-Hernández MJ. Alopecia areata: psychiatric comorbidity and adjustment to illness. Int J Dermatol. 2003;42(6):434–7.

Sampogna F, Raskovic D, Guerra L, Pedicelli C, Taboli S, Leoni L, et al. Identification of categories at risk for high quality of life impairment in patients with vitiligo. Br J Dermatol. 2018;179(2):351–8.

Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67(6):361–70.